| ENZC Stock | | | USD 0.0009 0.0001 10.00% |
Chairman
Harry Zhabilov is Chairman of the Board, CEO of Enzolytics since 2017.
| Age | 56 |
| Tenure | 7 years |
| Phone | 972 292 9414 |
| Web | https://enzolytics.com |
Enzolytics Management Efficiency
The company has return on total asset
(ROA) of
(7.0471) % which means that it has lost $7.0471 on every $100 spent on assets. This is way below average. Enzolytics' management efficiency ratios could be used to measure how well Enzolytics manages its routine affairs as well as how well it operates its assets and liabilities.
Enzolytics currently holds 233.12
K in liabilities. Enzolytics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Enzolytics until it has trouble settling it off, either with new capital or with free cash flow. So, Enzolytics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enzolytics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enzolytics to invest in growth at high rates of return. When we think about Enzolytics' use of debt, we should always consider it together with cash and equity.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Enzolytics [ENZC] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Enzolytics Leadership Team
Elected by the shareholders, the Enzolytics' board of directors comprises two types of representatives: Enzolytics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enzolytics. The board's role is to monitor Enzolytics' management team and ensure that shareholders' interests are well served. Enzolytics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enzolytics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Enzolytics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Enzolytics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Enzolytics Pink Sheet
Enzolytics financial ratios help investors to determine whether Enzolytics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Enzolytics with respect to the benefits of owning Enzolytics security.